Syncom Formulations (india) Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Syncom Formulations (india) Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $2.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Syncom Formulations (india) Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $2.5M Trade | TransData Nexus

Syncom Formulations (india) Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $2.5M Total Trade · DGFT Verified

Syncom Formulations (india) Limited is an Indian pharmaceutical exporter with a total trade value of $2.5M across 5 products in 3 therapeutic categories. Based on 285 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Chloroquine ($713.0K), Trimethoprim ($678.2K), Quinine ($647.1K).

Syncom Formulations (india) Limited — Export Portfolio & Destination Treemap

Syncom Formulations (india) Limited pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Syncom Formulations (india) Limited? — Company Overview & Market Position

Syncom Formulations (India) Limited, established in 1988, is a prominent player in the Indian pharmaceutical industry, specializing in the manufacturing, marketing, and sale of pharmaceutical formulations both domestically and internationally. The company operates through various segments, including the manufacturing and dealing in pharmaceutical drugs and formulations, trading of commodities, and renting of properties. Syncom's extensive product portfolio encompasses antibiotics, anthelmintics, antimalarials, cardiac medications, dermatologicals, gastrointestinal drugs, and more, available in diverse dosage forms such as tablets, capsules, liquids, injections, and effervescents.

The company's registered office is located at 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra 400093, India. Syncom Formulations is publicly listed on the Bombay Stock Exchange (BSE) under the ticker symbol 524470 and on the National Stock Exchange of India (NSE) under the symbol SYNCOMF. As of March 13, 2026, the stock price was ₹12.08, reflecting a market capitalization of approximately ₹1,224.82 million.

What Does Syncom Formulations (india) Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Chloroquine$713.0K

Product Portfolio — Top 5 by Export Value

Syncom Formulations (india) Limited exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Chloroquine	Antimalarial & Antiparasitic	$713.0K	113	0.4%	9
2	Trimethoprim	Advanced Antibiotics	$678.2K	85	2.6%	9
3	Quinine	Antimalarial & Antiparasitic	$647.1K	33	3.3%	5
4	Sulfamethoxazole	Advanced Antibiotics	$395.8K	43	2.0%	12
5	Acetylsalicylic	Combination Drugs	$70.0K	11	1.6%	12

Syncom Formulations (india) Limited exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $2.5M. The top category is Antimalarial & Antiparasitic (54.3% of portfolio), followed by Advanced Antibiotics (42.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Syncom Formulations (india) Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Syncom Formulations operates a state-of-the-art manufacturing facility in Pithampur, Madhya Pradesh, approximately 30 kilometers from Indore, the commercial capital of Madhya Pradesh. Established in 1995, this plant is WHO-GMP and ISO 9001-2015 certified, equipped with the latest production machinery to maintain high-quality standards. The facility manufactures and markets over 500 pharmaceutical formulation products in various dosage forms, including tablets, capsules, liquid orals, injections, dry syrups, ointments, creams, gels, and ophthalmic preparations.

3Key Leadership

The leadership team at Syncom Formulations is headed by Managing Director Vijay Shankarlal Bankda, who has been with the company since December 1, 1999. Ankit Kedarmal Bankda serves as the Executive Chairman, having been appointed on April 1, 2014. Rahul Vijay Bankda holds the position of Chief Financial Officer and President of Domestic Marketing. Other key executives include Vaishali Agrawal, Company Secretary and Compliance Officer, and Rakesh Chandra Srivastava, Chief Marketing Officer.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Syncom Formulations (india) Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Syncom Formulations has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its pharmaceutical formulations, enabling it to export products to these regions. Syncom's commitment to quality is demonstrated by its WHO-GMP and ISO 9001-2015 certifications, which are recognized internationally. These certifications facilitate market access and compliance with stringent regulatory standards in these regions.

2Emerging Markets

Syncom Formulations has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's marketing network spans around 25 countries worldwide, with over 400 products registered. This global footprint is supported by the company's WHO-GMP and ISO 9001-2015 certifications, which enhance its credibility and facilitate market entry in these regions.

3Geographic Strategy

Syncom Formulations demonstrates a diversified geographic strategy by operating in approximately 25 countries, including both regulated and emerging markets. This approach mitigates concentration risk and leverages growth opportunities across different regions. The company's strategic direction focuses on expanding its global footprint while maintaining high-quality standards, as evidenced by its WHO-GMP and ISO 9001-2015 certifications.

Syncom Formulations (india) Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Syncom Formulations has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), allowing it to export pharmaceutical formulations to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, seeking approval for marketing in the U.S. market. Syncom's commitment to quality is demonstrated by its WHO-GMP and ISO 9001-2015 certifications, which are recognized by the FDA and facilitate market access.

2WHO & EU GMP

Syncom Formulations holds WHO-GMP and ISO 9001-2015 certifications, which are recognized by the World Health Organization (WHO) and the European Union (EU). These certifications attest to the company's adherence to international quality standards in pharmaceutical manufacturing. The WHO-GMP certification is particularly significant for market access in various countries, as it is a prerequisite for exporting pharmaceutical products to many regions.

3CDSCO & Indian Regulatory

Syncom Formulations (india) Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Syncom Formulations operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly available, the company's diverse product portfolio and international certifications position it as a significant competitor in both domestic and international markets. The company's focus on quality, as demonstrated by its WHO-GMP and ISO 9001-2015 certifications, provides a competitive edge in the market.

2Key Differentiators

Syncom Formulations' key differentiators include its extensive product portfolio, encompassing over 500 pharmaceutical formulations in various dosage forms. The company's commitment to quality is underscored by its WHO-GMP and ISO 9001-2015 certifications, which are recognized internationally. Additionally, Syncom's global presence, with products registered in around 25 countries, demonstrates its ability to meet diverse market needs.

3Strategic Position

Syncom Formulations' current strategic direction focuses on expanding its global footprint while maintaining high-quality standards. The company's diverse product portfolio and international certifications support its strategy of catering to both regulated and emerging markets. Looking ahead, Syncom aims to leverage its manufacturing capabilities and global presence to drive growth and enhance its position in the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Syncom Formulations (india) Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Syncom Formulations has a track record of consistent export performance, with a total export value of $2.5 million USD and 285 shipments across five products in three therapeutic categories. The company's adherence to international quality standards, as evidenced by its WHO-GMP and ISO 9001-2015 certifications, indicates reliability in its manufacturing processes. The diverse product portfolio and global market presence further suggest a stable and consistent supply capability.

2Certifications to Verify

Importers should verify the following certifications when considering products from Syncom Formulations:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practice (WHO-GMP) certification to ensure adherence to international quality standards.

Frequently Asked Questions — Syncom Formulations (india) Limited

How many pharmaceutical products does Syncom Formulations (india) Limited export from India?

Syncom Formulations (india) Limited exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Chloroquine ($713.0K), Trimethoprim ($678.2K), Quinine ($647.1K), Sulfamethoxazole ($395.8K), Acetylsalicylic ($70.0K). Total export value is $2.5M.

What is Syncom Formulations (india) Limited's total pharmaceutical export value?

Syncom Formulations (india) Limited's total pharmaceutical export value is $2.5M, based on 285 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Syncom Formulations (india) Limited cover?

Syncom Formulations (india) Limited exports across 3 therapeutic categories. The largest are Antimalarial & Antiparasitic (54.3%, 2 products), Advanced Antibiotics (42.9%, 2 products), Combination Drugs (2.8%, 1 products).

Get Full Syncom Formulations (india) Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.